Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients

A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236as an Oral Tablet in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.

Inclusion Criteria:

• Diagnosis of COPD for 1 month
• Men or postmenopausal women
• Spirometry values indicating reduced lung function
• Smoking history equivalent to using 20 cigarettes a day for 10 years

Exclusion Criteria:

• Any current respiratory tract disorders other than COPD
• Requirement for regular oxygen therapy
• Use of oral or parenteral glucocorticosteroids within 30 days prior to the study